COMP <GO>
SMTI vs MRK // REVENUE GROWTH (YOY)
Sanara MedTech Inc. (NASDAQ) VS. Merck & Company Inc. (NYSE) • 15-METRIC TALLY: SMTI 4
— MRK 8
▲ REVENUE GROWTH (YOY) LEADER: SMTI
LAST: $32.92 (+0.11%) • MKT CAP: $302.4M
revenue-growth
19.00%
LAST: $146.33 (+3.83%) • MKT CAP: $361.02B
revenue-growth
1.30%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (SMTI VS. MRK)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | SMTI | MRK | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 92.70% | 74.80% | +17.90 | SMTI | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 16.30% | 20.70% | -4.40 | MRK | /roic <GO> |
| EV/EBITDA & P/E Valuation | 29.5x | 15.3x | +14.20 | MRK | /valuation <GO> |
| Free Cash Flow Yield | 0.71% | 3.42% | -2.71 | MRK | /fcf-yield <GO> |
| Operating Margin | 7.10% | 34.30% | -27.20 | MRK | /operating-margins <GO> |
| Net Profit Margin | 36.40% | 28.10% | +8.30 | SMTI | /net-margins <GO> |
| Revenue Growth (YoY) ACTIVE | 19.00% | 1.30% | +17.70 | SMTI | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.26% | -2.26 | MRK | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 3.25 | 5.19 | -1.94 | MRK | /balance-sheet <GO> |
| Piotroski F-Score Quality | 7/9 | 7/9 | 0.00 | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 30.4 | 51.7 | -21.30 | MRK | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | 0.92 | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | 6.8x | 18.4x | -11.60 | SMTI | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $302.4M | $361.02B | -$360.72B | MRK | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | SMTI REV | MRK REV | SMTI GROSS % | MRK GROSS % | SMTI FCF | MRK FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $103.1M | $65.01B | 92.7% | 74.8% | $2.2M | $12.36B |
| FY 2024 | $86.7M | $64.17B | 90.6% | 76.3% | -$229.6K | $18.10B |
| FY 2023 | $65.0M | $60.12B | — | — | -$3.2M | $10.30B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
SMTI // BETA —
MRK // BETA 0.92